- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | William Blair initiates Obsidian Therapeutics stock with outperform rating | 3 | Investing.com | ||
| OBSIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.08. | Obsidian Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.08. | Obsidian Therapeutics Completes Galera Merger And $350 Million Private Placement | 2 | pulse2.com | ||
| 05.08. | Piper Sandler initiates Obsidian Therapeutics stock with overweight | 2 | Investing.com | ||
| 05.08. | Piper Sandler startet Coverage für Obsidian Therapeutics Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| 05.08. | RTW Biotech Opp. - Obsidian Therapeutics merges with Galera | 2 | RNS | ||
| 04.08. | Galera Therapeutics, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics Completes Galera Therapeutics Merger with $350M Private Placement Financing | 2 | Contract Pharma | ||
| 03.08. | Obsidian Therapeutics completes merger with Galera | 1 | Investing.com | ||
| 03.08. | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | 765 | Business Wire | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| 31.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 15.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.04. | Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc. Announce Merger Agreement and $350 Million Concurrent Private Placement | 328 | Business Wire | • Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian's pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.
• Obsidian's... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 41,260 | +1,21 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| NOVOCURE | 10,615 | +0,38 % | Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya for Brain Metastases from Non-Small Cell Lung Cancer | Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,981 | +7,81 % | Spero Therapeutics beruft William Ho in das Board of Directors - Patrick Vink tritt zurück | ||
| PRECISION BIOSCIENCES | 8,300 | -2,35 % | Precision BioSciences announces $125M public offering; shares up | ||
| BOLT BIOTHERAPEUTICS | 6,300 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus |
OBSIDIAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 13,735 Euro und damit -0,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OBSIDIAN THERAPEUTICS INC finden Sie auf Wallstreet Online.